Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Date
2012
Author
Skjoth, Trine Vang
Damci, Taner
Donnet, Jean-Paul
Endahl, Lars
Vaag, Allan
Niskanen, Leo
Leiter, Lawrence A.
Franek, Edward
Weng, Jianping
Munoz-Torres, Manuel
Metadata
Show full item record
Abstract
Objective: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).
URI
http://hdl.handle.net/20.500.12627/37025
https://doi.org/10.1530/eje-12-0293
Collections